Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00522379 · ClinicalTrials.gov registry record · Phase 3

Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch

A Phase 3 study of Parkinson's Disease, sponsored by UCB Pharma.

Completed
Registry status
Phase 3
Development phase
514
Enrollment target
20
Study locations

NCT00522379 is a Phase 3 study of Parkinson's Disease that has completed, run by UCB Pharma. The registered enrollment target is 514 participants, below the 639-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (20% lower). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00522379, a Phase 3 study of Parkinson's Disease, has completed, sponsored by UCB Pharma.

COMPLETED
Registry status
Phase 3
Development phase
514 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to show Rotigotine dose response at four doses of Rotigotine used with L-dopa in treating advanced stage Parkinson's disease.

Conditions Studied

Parkinson's Disease

Interventions

  • OTHER Placebo
  • DRUG Rotigotine

Study Locations (20)

California

  • - Fountain Valley
  • - Fresno
  • - Irvine
  • - La Jolla
  • - Loma Linda
  • - Oxnard

Florida

  • - Boca Raton
  • - Bradenton
  • - Jacksonville
  • - Miami
  • - Naples

Arizona

  • - Gilbert
  • - Peoria
  • - Phoenix
  • - Scottsdale

Alabama

  • - Birmingham
  • - Tuscaloosa

Arkansas

  • - Little Rock

Colorado

  • - Aurora

Connecticut

  • - New Haven

Trial Details

FieldValue
Enrollment Target 514 participants
Start Date 2007-07
Est. Completion 2011-07
Phase Phase 3

Sponsor

UCB Pharma

100 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00522379

The ClinicalTrials.gov registry entry for NCT00522379 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 514 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 639-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (20% lower). The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00522379 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT00522379 about?

NCT00522379 is a clinical study titled "Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch". The purpose of this study is to show Rotigotine dose response at four doses of Rotigotine used with L-dopa in treating advanced stage Parkinson's disease.

What is the current status of trial NCT00522379?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 514 participants. The study started on 2007-07. Estimated completion is 2011-07.

What conditions does trial NCT00522379 study?

This clinical trial studies the following conditions: Parkinson's Disease.

What interventions are being tested in trial NCT00522379?

The interventions under investigation include: Placebo (OTHER), Rotigotine (DRUG).

Who is sponsoring clinical trial NCT00522379?

This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00522379 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Parkinson's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Parkinson's Disease

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.